CRISPR Therapeutics
CRSP
CRSP
39 hedge funds and large institutions have $155M invested in CRISPR Therapeutics in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
26% less capital invested
Capital invested by funds: $211M → $155M (-$55.7M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $322K
Holders
39
Holding in Top 10
2
Calls
$1K
Puts
$322K
Top Buyers
| 1 | +$11.7M | |
| 2 | +$2.79M | |
| 3 | +$966K | |
| 4 |
Millennium Management
New York
|
+$529K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$321K |
Top Sellers
| 1 | -$16.3M | |
| 2 | -$2.5M | |
| 3 | -$941K | |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$473K |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$443K |